相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace et al.
GUT (2018)
Review of cancer treatment with immune checkpoint inhibitors
Christiane Thallinger et al.
WIENER KLINISCHE WOCHENSCHRIFT (2018)
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer
Takayuki Shiroyama et al.
CANCER MEDICINE (2018)
Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population
Y. Fujisawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
Mehmet Asim Bilen et al.
CLINICAL GENITOURINARY CANCER (2018)
Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab
Wungki Park et al.
CLINICAL LUNG CANCER (2018)
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
Alessandro Russo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
Danielle Benedict Sacdalan et al.
ONCOTARGETS AND THERAPY (2018)
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Samuel Rosner et al.
CANCER MEDICINE (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
Koung Jin Suh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)
Roger Sun et al.
EUROPEAN JOURNAL OF CANCER (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma A meta-analysis
Jun Yin et al.
MEDICINE (2017)
Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
Xu Liu et al.
MEDICINE (2017)
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Minkyu Jung et al.
CANCER RESEARCH AND TREATMENT (2017)
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Ghayathri Jeyakumar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M. Hopkins et al.
BRITISH JOURNAL OF CANCER (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model
Hu Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Prognostic Significance of Neutrophil-toLymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies
Qi-tao Huang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
Tomohiro F. Nishijima et al.
CANCER TREATMENT REVIEWS (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
Katrin Moses et al.
SEMINARS IN IMMUNOLOGY (2016)
Adapting Cancer Immunotherapy Models for the Real World
Lairyn E. Klevorn et al.
TRENDS IN IMMUNOLOGY (2016)
The Role of Prostaglandin E-2 in Tumor-Associated Immunosuppression
Dingzhi Wang et al.
TRENDS IN MOLECULAR MEDICINE (2016)
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma
Leila Khoja et al.
CANCER MEDICINE (2016)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
P. F. Ferrucci et al.
BRITISH JOURNAL OF CANCER (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
Global cancer transitions according to the Human Development Index (2008-2030): a population-based study
Freddie Bray et al.
LANCET ONCOLOGY (2012)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
分享论文
